RegASK regulatory intelligence experts highlight five regulatory trends that stood out across life sciences between 25 July and 25 August 2026.
Between 25 July and 25 August 2026, RegASK’s regulatory intelligence experts tracked developments affecting medicines, medical devices, clinical trials and digital health across multiple regions.
Five themes stood out for their regulatory momentum and potential impact on life sciences teams: modernization of post-market safety systems, wider use of regulatory reliance, coordinated attention on GLP-1 receptor agonists, evolving clinical-trial standards, and the growing role of AI and digital tools in regulation.
Here are the five trends to watch.
Post-market safety systems are modernizing worldwide
Trend strength: High
Post-market safety and pharmacovigilance was the broadest life sciences theme during the reporting period, with around 30 developments spanning eight regions and 18 jurisdictions.
Regulators are updating the infrastructure used to identify, report and act on safety signals.
Brazil’s ANVISA opened consultations covering a National Pharmacovigilance System and technovigilance reform ANVISA. South Africa’s SAHPRA launched VigiFlow e-reporting SAHPRA, while Argentina’s ANMAT introduced a new adverse-event reporting form. ANMAT Mexico’s COFEPRIS also published a national safety COFEPRIS.
At the same time, regulators continued responding to active safety signals. In Europe, PRAC activity led to new safety communications, including a BfArM direct healthcare professional communication on meningioma risk associated with desogestrel and etonogestrel.
Australia’s TGA also opened a post-market review of syringes and consulted on greater transparency around medical-device safety.
Taken together, these developments point toward more structured, digital and continuous approaches to post-market surveillance.
What this means for regulatory teams
Pharmacovigilance and post-market monitoring are becoming increasingly embedded in regulatory infrastructure.
Teams need to track both individual safety signals and changes to the systems through which adverse events, device incidents and emerging risks are reported and managed.
Regulatory reliance and accelerated-access pathways are expanding
Trend strength: High
Regulatory reliance was another major theme during the reporting period, with around 31 developments across North America, the Middle East, the EAEU, Europe, the UK and international regulatory bodies.
The direction is increasingly clear: regulators are creating pathways that allow them to make greater use of assessments or decisions from trusted authorities.
Health Canada’s Ministerial Reliance Order came into force on 15 July, alongside consultation on a foreign-reliance pathway.
Saudi Arabia’s SFDA introduced its Rapid Access to Innovative Drugs designation and became the first regulator to register iberdomide SFDA The UAE also authorized novel medicines shortly afterward.
At the international level, WHO published its first interim list of Transitional WHO-Listed Authorities for medical devices.
In the UK, MHRA activity through the Innovative Licensing and Access Pathway also supported accelerated authorization, including the European authorization of oral orforglipron.
The broader trend is a shift toward reliance pathways that are increasingly operational rather than simply under discussion.
What this means for regulatory teams
Global submission strategies may need to account for a growing number of reliance and accelerated-access pathways.
Understanding which regulators recognize external assessments, what evidence is required and when a product may qualify could influence filing sequences and market-access planning.
GLP-1 receptor agonists are becoming a coordinated global regulatory story
Trend strength: Medium
Supplements and functional products are also moving toward more structured oversight.
Trend strength: High
GLP-1 receptor agonists stood out as a distinct regulatory theme during the reporting period, with market expansion and safety oversight developing in parallel.
WHO advisory committees issued a joint statement on the safe and appropriate use of GLP-1 receptor agonists, bringing coordinated international attention to the class.
At the same time, oral orforglipron received regulatory approvals across several markets within a short period, including the UK MHRA Saudi Arabia under the name Foundayo, SFDA and the UAE EDE.
The combination is significant.
As the class expands into more markets, regulators are also establishing a broader framework for monitoring appropriate use and safety.
What this means for regulatory teams
GLP-1 receptor agonists now warrant dedicated regulatory monitoring across approvals, safety communications and post-market requirements.
For companies operating in or around the category, a class-level view may be more useful than monitoring individual products or markets separately.
Clinical-trial standards are converging while eligibility broadens
Trend strength: Medium-high
Clinical-trial regulation is moving toward greater international alignment alongside efforts to broaden participation.
ICH E6(R3) Good Clinical Practice became the operative reference standard from 15 July, providing an updated framework for the conduct of clinical trials.
In the US, FDA finalized three guidances addressing eligibility criteria in cancer clinical trials, covering performance status, laboratory values, and washout periods and concomitant medications. FDA also ran its Expedited IND pilot.
Elsewhere, India’s CDSCO ICMR on the use of a single ethics-committee review for multicenter trials, while Health Canada launched a public clinical-trials search portal.
Together, these developments point toward more modernized trial standards, streamlined oversight and deliberate efforts to broaden participation.
What this means for regulatory teams
Clinical teams need to account for both changes to GCP expectations and evolving national approaches to trial design and oversight.
Eligibility criteria, ethics review and transparency requirements can all affect protocol development, site planning and regulatory submissions.
AI and digital tools are moving deeper into medicines regulation
Trend strength: Medium
Regulators are also building frameworks for AI-enabled products, digital tools and new forms of regulatory information.
The EU AI Act became generally applicable on 2 August, creating a wider regulatory backdrop for organizations developing or deploying AI systems.
In the UK, the MHRA launched an AI health-innovation regulatory sandbox with NHS England.
At the international level, the International Medical Device Regulators Forum advanced its technical framework for AI lifecycle management in medical devices through N93.
Brazil also moved forward with digital medication package inserts.
These developments are still at different stages of maturity, but together they show regulators working on AI governance and digital regulatory infrastructure at the same time.
What this means for regulatory teams
AI and digitalization are becoming relevant across more parts of the regulatory lifecycle.
Teams need to monitor requirements affecting AI-enabled products as well as changes to the regulatory processes, information formats and oversight mechanisms surrounding them.
What connects these five trends?
Across the 25 July to 25 August reporting period, life sciences regulators were focused on two priorities at once: speeding access to innovation while strengthening the systems that govern safety, evidence and oversight.
That balance appears across all five trends.
Reliance pathways are creating opportunities for faster approvals. Clinical-trial rules are being modernized. AI and digital tools are entering regulatory systems. At the same time, pharmacovigilance infrastructure is becoming more structured, and regulators are coordinating more closely around emerging safety issues.
For regulatory teams, understanding the individual development is only the beginning. They also need to know:
- which products, markets and submissions may be affected
- whether new reliance or accelerated pathways are available
- how clinical, safety or post-market requirements are changing
- where new digital or AI requirements could create additional obligations
These five themes reflect the life sciences developments that stood out in RegASK’s regulatory monitoring between 25 July and 25 August 2026.
RegASK monitors regulatory developments across 160+ markets, supported by a global community of more than 1,800 regulatory experts, giving life sciences teams the intelligence they need to understand regulatory change, assess its impact and act across their workflows.
